755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICSPietro Lampertico, M. Colombo, G. Gubertini et al.|Journal of Hepatology|2013Cited by 24
522 MAINTAINED VIRAL SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A 4-YEAR FIELD PRACTICE, MULTICENTER STUDYPietro Lampertico, M. Colombo, R. Soffredini et al.|Journal of Hepatology|2012Cited by 10
OC.09.2: MAINTAINED LONG-TERM SUPPRESSION OF HBV REPLICATION IN NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH ETV MONOTHERAPY IN FIELD PRACTICE: THE ITALIAN MULTICENTER EXPERIENCEPietro Lampertico, C Massimo, Mauro Viganò et al.|Digestive and Liver Disease|2011Cited by 8
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD)Gaetano Bergamaschi, Veronica Marasco, Fabiana Castiglione et al.|Digestive and Liver Disease|2024Cited by 6
T-11 5-year entecavir in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety but no prevention of HCCPietro Lampertico, M. Colombo, R. Soffredini et al.|Digestive and Liver Disease|2013Cited by 1